logo
Plus   Neg
Share
Email

Genentech's Late-stage Study On Aggressive Leukemia Meets Primary Endpoints

Genentech, a member of the Roche Group (RHHBY), said that the late-stage VIALE-A study met its dual primary endpoints of overall survival and composite complete remission rate.

The study showed Venclexta plus azacitidine helped people with the most common type of aggressive leukemia in adults live longer compared to azacitidine alone.

Safety for Venclexta plus azacitidine appeared consistent with the known safety profile of these medicines.

Venclexta is being developed by AbbVie and Genentech. It is jointly commercialized by the companies in the United States and commercialized by AbbVie outside of the United States.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Beginning July 6, Google plans to reopen offices in more cities, which were closed following the coronavirus pandemic-related lockdowns across the globe, Chief Executive Officer Sundar Pichai told employees in an email. However, the search giant still expects and encourages most Googlers to largely work from home for the rest of 2020. For those working from home, the company offered an allowance. Bristol Myers Squibb (BMY) announced Wednesday that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. With the EC marketing authorization,... Off-price retailer Tuesday Morning Corp. (TUES) on Wednesday filed voluntary petitions for protection under Chapter 11 of the Bankruptcy Code in the U. S. Bankruptcy Court for the Northern District of Texas, Dallas Division. It plans to emerge as a stronger company by early fall 2020. The company...
Follow RTT